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Abstract
Background: HTLV-I is the causal agent of adult T cell leukemia (ATLL) and HTLV-I-associated
myelopathy/tropical spastic paraparesis (HAM/TSP). Biomarkers are needed to diagnose and/or
predict patients who are at risk for HAM/TSP or ATLL. Therefore, we investigated using luciferase
immunoprecipitation technology (LIPS) antibody responses to seven HTLV-I proteins in non-
infected controls, asymptomatic HTLV-I-carriers, ATLL and HAM/TSP sera samples. Antibody
profiles were correlated with viral load and examined in longitudinal samples.
Results: Anti-GAG antibody titers detected by LIPS differentiated HTLV-infected subjects from
uninfected controls with 100% sensitivity and 100% specificity, but did not differ between HTLV-I
infected subgroups. However, anti-Env antibody titers were over 4-fold higher in HAM/TSP
compared to both asymptomatic HTLV-I (P < 0.0001) and ATLL patients (P < 0.0005). Anti-Env
antibody titers above 100,000 LU had 75% positive predictive value and 79% negative predictive
value for identifying the HAM/TSP sub-type. Anti-Tax antibody titers were also higher (P < 0.0005)
in the HAM/TSP compared to the asymptomatic HTLV-I carriers. Proviral load correlated with
anti-Env antibodies in asymptomatic carriers (R = 0.76), but not in HAM/TSP.
Conclusion: These studies indicate that anti-HTLV-I antibody responses detected by LIPS are
useful for diagnosis and suggest that elevated anti-Env antibodies are a common feature found in
HAM/TSP patients.
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Background
Human T lymphotropic virus type I (HTLV-I) is a retrovi-
rus that infects 20 million people worldwide [1]. HTLV-I
infection can cause a variety of human diseases including
adult T-cell leukemia/lymphoma (ATLL) [2-4], HTLV-I
associated myelopathy/Tropical Spastic Paraparesis
(HAM/TSP) [5], infective dermatitis [6], and uveitis [7].
While the two major HTLV-I-associated diseases, ATLL
and HAM/TSP, are present in all endemic areas, including
Japan, the Caribbean basin, South America and parts of
Africa, the incidence rates show geographic heterogeneity
[1]. ATLL is an aggressive monoclonal proliferation of
HTLV-1 infected CD4+ T cells that occurs mostly in adults.
Perinatal HTLV-I infection is thought to be associated
with a heightened risk of developing ATLL after a long
latency period. Although the pathogenesis of ATLL is not
completely understood, the HTLV-I regulatory protein Tax
plays a critical role in cellular transformation by interfer-
ing with genome instability, cell cycle and apoptosis [8].
HAM/TSP is a chronic progressive neurodegenerative dis-
order that involves demyelination of the spinal cord and
is characterized by CNS perivascular infiltration of inflam-
matory cells [9]. Epidemiological studies indicate that
acquiring HTLV-I infection later in life through sexual
contacts or through blood transfusion are linked to the
future development of HAM/TSP a short time after infec-
tion. While HAM/TSP patients have high levels of anti-
HTLV-I antibodies [10,11], lower anti-Tax antibodies are
often found in ATLL patients, which may be due in part to
Tax mutations that allow viral escape from cytotoxic T-
lymphocyte (CTL) responses [12,13]. HAM/TSP patients
show high HTLV-I proviral loads in peripheral blood lym-
phocytes [14-16] and increased spontaneous lymphopro-
liferation in vitro [17-19]. HAM/TSP patients also have
high levels of HTLV-I-specific CTLs that have been
reported to play an immunopathogenic role [20-22]. On
the other hand, ATLL patients commonly exhibit immun-
odeficiency [23] and show ineffective anti-HTLV-I cell-
mediated immunity [24].
Although there are adequate methods for determining if
people are infected with HTLV-I, there are no serological
diagnostic tests available for discriminating asymptomatic
carriers from HAM/TSP patients or ATLL patients. Cur-
rently HTLV-I diagnosis is performed by immunoassays
for HTLV-I gene products, HTLV-I-specific antibody pro-
duction, detection of HTLV-I DNA, Southern blotting for
ATLL diagnosis and more recently, proteomic approaches
[25]. The ability to clearly distinguish between clinical
outcomes of HTLV-I infections in a robust and simple
serological test would have obvious clinical utility.
Currently, most immunoassays measuring anti-HTLV-I
antibodies do not quantitatively evaluate multiple anti-
gens and are incapable of detecting conformational
epitopes in these antigens. We recently developed a highly
sensitive immunoprecipitation technology called Luci-
ferase Immunoprecipitation System (LIPS) that utilizes
mammalian cell-produced, recombinant fusion protein
antigens for efficiently evaluating antibody responses to
multiple viral proteins and even a full virus proteome
[26]. Here, LIPS was used to profile antibody responses to
seven different HTLV-I proteins to gain a better under-
standing of the anti-HTLV-I antibody responses in non-
infected controls, asymptomatic HTLV-I-carriers, HAM/
TSP and ATLL sera samples. In addition to determining
the prevalence of antibodies to these different proteins in
HTLV-infected individuals, antibody titers were analyzed
for correlations with HAM/TSP and ATLL clinical pheno-
types, as well as proviral load.
Results
Diagnostically useful anti-Gag antibody titers are present 
in all HTLV-I infected individuals
Sera samples analyzed in this study were derived from 115
well-characterized participants including healthy volun-
teers, asymptomatic HTLV carriers, ATLL, and HAM/TSP
patients. The gender, race/ethnic group and mean age of
sample acquisition are summarized in Table 1.
While most previous studies evaluating anti-HTLV-I anti-
bodies have used processed proteins of Gag such as p19
and p24, the full-length Gag was used in LIPS. Using the
Cos1 cell containing fusion protein extracts, two inde-
pendent measurements were made with 115 blinded sera
in the LIPS format. From the average of these tests, the
anti-Gag antibody titers showed values in the 115 sera
ranging from 0 to 231,132 LU (Figure 1). The mean ±
standard deviation (SD) of the anti-Gag antibody titer in
the 42 normal HTLV-I seronegative controls was 123 ±
150 LU and it was significantly different (P  < 0.0001)
from the mean value of 143,250 ± 56,169 LU for the con-
firmed 73 HTLV-I infected samples including the asymp-
tomatic carriers, ATLL and HAM/TSP samples. Using a
value of 875 LU as a cut-off derived from the mean plus 5
SD of the controls revealed 100% sensitivity (73/73) and
100% specificity in detecting positive anti-Gag antibodies
in the known HTLV-I positive samples. Some of weak
background signals seen in control samples were below
the cut-off value and were dramatically lower than any of
the HTLV-I positive samples. While the anti-Gag antibody
was highly useful for the diagnosis of HTLV-I infection,
the mean anti-Gag antibody titers were not statistically
different between the 15 asymptomatic HTLV-I carriers,
18 ATLL and 40 HAM/TSP HTLV-I positive patient groups
(Figure 1).Retrovirology 2008, 5:96 http://www.retrovirology.com/content/5/1/96
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Table 1: Characteristics of the participants used in the study
Healthy Donor (n = 42) ATL (n = 18) Asymptomatic (n = 15) HAM/TSP (n = 40)
Sex-no. (%)
Male 26 (61.9%) 7 (38.9%) 4 (26.7%) 15 (37.5%)
Female 8 (19.0%) 11 (61.1%) 10 (66.7%) 25 (62.5%)
Unknown 8 (19.0%) 1 (6.7%)
Race or Ethnic Group-no.
White 20 (47.6%) 2 (11.1%) 5 (33.3%) 9 (22.5%)
African descent 10 (23.8%) 15 (83.3%) 4 (26.7%) 19 (47.5%)
Hispanic 3 (7.1%) 1 (5.6%) 5 (33.3%) 3 (7.5%)
Unknown 9 (21.4%) 1 (6.7%) 9 (22.5%)
Age at Sample Acquisition
Mean (yr) 44 46 54 54
LIPS detection of anti-HTLV-I Gag antibodies Figure 1
LIPS detection of anti-HTLV-I Gag antibodies. Each symbol represents individual samples from normal control, asymp-
tomatic HTLV-infected, ATLL, and HAM/TSP patients. Antibody titers in LU are plotted on the Y-axis using a log10 scale. The 
dashed line represents the cut-off level for determining sensitivity and specificity for the particular antigen and is derived from 
the mean plus 5 SD of the antibody titer of the 42 normal volunteer samples. P values were calculated using the Mann Whitney 
U test. The solid line indicates the mean antibody titer per group.
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Anti-Env antibodies are markedly elevated in HAM/TSP 
compared to ATLL or asymptomatic HTLV-I-carriers
Anti-Env antibodies were also evaluated in the 115 sera
samples (Figure 2). While the 42 normal HTLV-I seroneg-
ative control samples showed anti-Env antibody titers
with a mean and SD of 730 ± 599 LU, the 73 known
HTLV-I infected sera samples had a 300-fold higher mean
and SD of 222,158 ± 232,681 LU. A Mann-Whitney U test
showed a marked statistical difference in anti-Env anti-
body titers between the controls and HTLV-I infected
patients (P < 0.0001). A cut-off of the mean plus 5 SD of
the control subjects revealed 85% sensitivity (62/73) and
100% specificity in detecting positive anti-Env antibodies
in the HTLV-I positive samples. The anti-Env antibody
responses were less useful than the anti-GAG antibody tit-
ers to discriminate HTLV-I infected from uninfected con-
trols and this is reflected by the slightly lower area under
the curve (AUC) value of 0.95 for anti-Env antibodies
verses 1.00 for the anti-Gag antibody test as determined
by analyzing receiver-operating characteristics (ROC).
As shown in Figure 2, analysis of the mean anti-Env anti-
body titers in the different HTLV-infected groups revealed
that the HAM/TSP patients had much higher serum anti-
body titers than the 18 ATLL or 15 asymptomatic HTLV-I-
carriers. The mean anti-Env antibody titer in the HAM/
TSP patients was 345,176 ± 232,983 LU, while the ATLL
and asymptomatic HTLV-I-infected patients had mean tit-
ers of 82,825 ± 125,784 LU and 61,310 ± 109,976 LU,
respectively. A Mann Whitney U test showed that the anti-
Env antibody titers in the HAM/TSP patients were mark-
edly different than the asymptomatic HTLV-I carriers (P <
0.0001) and ATLL patients (P < 0.0005). In contrast, the
anti-Env antibody titers were not statistically different
LIPS detection of anti-Env antibodies Figure 2
LIPS detection of anti-Env antibodies. Each symbol represents an average of two independent measurements from indi-
vidual samples from normal control, asymptomatic HTLV-infected, ATLL, and HAM/TSP patients. The solid line indicates the 
mean antibody titer per group.
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between the asymptomatic HTLV-I-infected and ATLL
patients (P = 0.1782).
Inspection of patient characteristics did not reveal any
obvious differences that explained the 4 ATLL and 4
asymptomatic HTLV-I-infected outliers with relatively
high anti-Env antibody titers (Figure 2). For example, the
patient characteristics (age, range 36–74; gender, one
male and three females; race, one white and three African
descent; or country of origin, one Jamaican; three U.S.) of
the 4 asymptomatic HTLV-I-infected individuals showed
no consistent pattern and none of these 4 individuals
developed HAM/TSP during a 2–5 year follow-up. Fur-
thermore, none of the ten HAM/TSP subjects with rela-
tively low anti-Env antibody titers as a group significantly
differed from the HAM/TSP cohort with respect to age,
gender race or country of origin. However, all ten HAM/
TSP patients were not classified as rapid progressors and
three of the ten had a history of treatment with anti-retro-
virals.
LIPS analysis of anti-Tax antibodies
HTLV-I Tax is a major regulator of gene expression in the
human host and several studies have suggested anti-Tax
antibodies are involved in the pathogenesis of HAM/TSP
[27,28]. Using LIPS, the anti-Tax antibody response
showed a wide dynamic titer range varying from 0 to 1.3
million LU in the entire sample set (Figure 3). The 42 nor-
mal HTLV-I seronegative control samples had a low mean
anti-Tax antibody titer of 560 LU ± 826 LU. In contrast,
the anti-Tax antibody titers for the 73 HTLV-I infected
samples were almost 1000 times higher with a mean value
Detection of positive anti-Tax antibodies Figure 3
Detection of positive anti-Tax antibodies. Each symbol represents an individual sample from normal control, asympto-
matic HTLV-infected, ATLL, or HAM/TSP patients. The solid line indicates the mean antibody titer per group.
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of 449,609 ± 223,747 LU (P < 0.0001). Using a cut-off of
the mean plus 5 SD of the control subjects revealed 85%
sensitivity (14/15) in detecting positive anti-Tax antibod-
ies in the HTLV-I asymptomatic carriers and 98% sensitiv-
ity (39/40) in detecting positive anti-Tax antibodies in the
HAM/TSP samples. In the case of the ATLL samples, 100%
(18/18) were found to have anti-Tax positive titers.
Inspection of the mean anti-Tax antibodies among the dif-
ferent HTLV-I infected groups showed that the 40 HAM/
TSP patients had a mean anti-Tax antibody titer of
518,849 LU that was close to twice the mean value of
282,900 LU for the asymptomatic HTLV-I carriers. This
elevated anti-Tax antibody in the HAM/TSP patients com-
pared to the asymptomatic HTLV-I carriers was highly sta-
tistically significant (P < 0.0001). In contrast, no statistical
difference (P = 0.1815) was found between the mean anti-
Tax antibody titer of the HAM/TSP and ATLL samples.
Few detectable antibody responses to other HTLV-I 
antigens
A previous study using LIPS to profile HIV-infected
patients' humoral responses to the entire HIV proteome
revealed antibody responses to all HIV proteins including
the HIV reverse transcriptase and minor accessory proteins
such as Rev and Vif [26]. To determine if LIPS could detect
antibody responses to additional HTLV-I proteins, we
tested for antibodies to HTLV-I encoded p12, p30, Rex
and reverse transcriptase. While no detectable anti-p12,
anti-p30 or anti-reverse transcriptase antibodies were
detected (data not shown), several of the HTLV-I infected
sera showed positive immunoreactivity towards Rex.
Using a cut-off of 3,907 LU, the mean plus 5 SD of the
anti-Rex antibody titers in the control samples, three
HTLV-I positive sera were detected, comprised of two
HAM/TSP samples with titers of 60,958 LU and 1.35 mil-
lion LU and one ATLL sample with a titer of 92,044 LU. It
should be noted that these anti-Rex antibody positive
samples may represent high anti-HTLV-I antibody
responding patients because all 3 of these samples were
also positive for anti-Gag, anti-Env, and anti-Tax antibod-
ies.
Correlation of antibody titers with HTLV-I proviral load
Recent studies indicate that higher HTLV-I proviral loads
correlate with HAM/TSP [29,30]. In agreement with these
studies, the mean HTLV-I proviral loads in the HAM/TSP
patients were three-fold higher than the HTLV-I asympto-
matic patients, which was statistically significant (P  =
0.0067). Comparison by regression analysis of the HTLV-
I proviral load with the HTLV-I antibody titer data
revealed that there was no significant correlation between
the different antibody titers determined by LIPS and the
proviral load in the HAM/TSP patients. For example as
shown in Figure 4A, the correlation between the anti-Env
antibody titers and proviral load in HAM/TSP patients
showed a Pearson correlation coefficient of only (R  =
0.18, P = 0.345). In contrast, anti-Env antibody titers from
asymptomatic HTLV-I carriers markedly correlated (Pear-
son R = 0.76; P = 0.003) with the HTLV-I proviral load
(Figure 4B). Based on the covariance, the anti-Env anti-
bodies explained 49% of the proviral load levels in the
asymptomatic HTLV-I infected patients. In asymptomatic
carriers, anti-Gag and anti-Tax antibody titers had no sig-
nificant relationship with HTLV-I proviral load (data not
shown). Together these results suggest that anti-Env anti-
body titers determined by LIPS may be a weak marker for
the level of virus present in the blood of asymptomatic
HTLV-I-infected patients, but not in HAM/TSP patients.
HTLV-I antibody titers are relatively stable in longitudinal 
samples
An additional set of blinded serial samples (n = 76) from
a number of selected patients were also analyzed for anti-
Gag, anti-Env, and-Tax antibodies. Representative results
from several of these patients are shown in Figure 5, in
which the anti-Gag, anti-Env, and anti-Tax antibody titers
were relatively stable in both the asymptomatic HTLV-I
carriers and HAM/TSP.
Antibody profiles versus HTLV-I clinical phenotypes
Several of the HTLV-I antigens showed markedly higher
antibody titers in HAM/TSP patients compared to ATLL
and asymptomatic HTLV-I carriers. Therefore, ROC analy-
sis was used to evaluate the most useful antibody markers.
The anti-Env antibody titer showed the best discrimina-
tive power for identifying patients with HAM/TSP versus
asymptomatic HTLV-I carriers and ATLL, as shown by the
large AUC value of 0.83 from the ROC curve. Anti-Tax and
anti-Gag antibodies were still informative but had lower
AUC values of 0.72 and 0.61, respectively (data not
shown). When a cutoff threshold greater than 100,000 LU
was applied to the anti-Env antibody titers, the sensitivity
and specificity for identifying HAM/TSP patients versus
ATLL and asymptomatic HTLV-I carriers were 81% and
72%, respectively (Table 2). Using this 100,000 LU cut-
off, the odds ratio for HAM/TSP versus ATL and asympto-
matic was 11.1 (95% confidence interval 3.7–33.5). The
presence of anti-Env antibody titers above 100,000 LU
provides a fairly useful diagnosis (sensitivity 81%; specif-
icity 72%; positive predictive value 75%) and shows the
importance of monitoring these antibodies. For compari-
son, a higher cutoff value of greater than 200,000 LU
yielded a sensitivity of 85% sensitivity and 70% specificity
with an odds ratio of 13.1 (95% confidence interval 4.1–
42.0). Additional analysis separately comparing the
HAM/TSP patient with either asymptomatic HTLV-I carri-
ers or ATLL yielded similar values (Table 2). For example,
using the 100,000 LU cut-off of HAM/TSP versus asymp-
tomatic patients yielded a sensitivity of 91% and 55% spe-Retrovirology 2008, 5:96 http://www.retrovirology.com/content/5/1/96
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cificity with an odds ratio of 12.0 (95% confidence
interval 2.8–51.4). Lastly, incorporation of anti-Tax and
anti-Gag antibody titers into the HAM/TSP diagnostic
algorithm did not significantly improve the sensitivity or
specificity of the test (data not shown). This is because
many of the samples positive for anti-Tax and anti-Gag
antibodies were already positive for anti-Env antibodies
and several additional false positives would have been
detected in the asymptomatic HTLV-I carrier and ATLL
groups.
Discussion
LIPS technology provided quantitative measures of anti-
body titers to most of the proteins of HTLV-I. This simple
modular system, expressing HTLV-I antigens as a series of
Ruc fusion proteins followed by standardized chemilumi-
nescent detection, efficiently evaluated patient humoral
response to these different HTLV-I antigens. The substan-
tial difference in anti-Gag antibody titers between the
HTLV-I-infected samples and normal HTLV-I seronegative
controls as determined by LIPS allowed for a universal
and rigorous statistical cut-off (the mean of the 42 con-
trols plus 5 standard deviations). Of the 7 antigens tested
for diagnosing HTLV-I infection, the anti-Gag antibody
test was the most informative, achieving 100% sensitivity
and 100% specificity. The LIPS assay likely detects more
conformational epitopes than alternative immunoassay
formats providing high sensitivity, high specificity and
robust signals that provide a substantial and clear distinc-
tion between positive and negative HTLV-I sera. Addition-
ally, the high-throughput format used here makes this
approach highly feasible for screening large numbers of
sera samples.
From our LIPS studies profiling 7 different HTLV-I anti-
gens, anti-Env antibody titers significantly correlated with
the proviral load in asymptomatic HTLV-I seropositive
samples (R = 0.76; P = .003). These results suggest that
anti-Env antibody titers detected by LIPS may have utility
in monitoring HTLV-I proviral load in asymptomatic indi-
viduals. This correlation between anti-ENV antibody titers
and proviral load was unique to HTLV-I seropositive
asymptomatic patients and consistent with previous stud-
ies demonstrating HTLV-I proviral load associations with
anti-HTLV-I antibodies [12,13]. We now can suggest that
in asymptomatic carriers, this correlation with HTLV-I
proviral load was specific for antibodies to the Env region
of HTLV-I. Of interest was the observation that anti-Env
antibodies did not correlate with HTLV-I proviral loads in
HAM/TSP patients. This may reflect higher levels of HTLV-
Anti-Env antibody titer in asymptomatic HTLV-I-infected carriers correlates with the proviral load Figure 4
Anti-Env antibody titer in asymptomatic HTLV-I-infected carriers correlates with the proviral load. Asympto-
matic HTLV-I-infected patients and HAM/TSP patients were evaluated for proviral load as described in the material and meth-
ods. (A.) Linear regression analysis showed that the anti-Env antibody titer determined by LIPS did not correlate in HAM/TSP 
patients. (B.) In contrast, proviral load significantly correlated (Pearson correlation R = 0.76) with anti-ENV antibody titers in 
asymptomatic HTLV-I carriers.
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Longitudinal analysis of HTLV-I anti-Env, Gag, and Tax antibody responses Figure 5
Longitudinal analysis of HTLV-I anti-Env, Gag, and Tax antibody responses. Data is plotted for two representative 
untreated HAM/TSP patients (left) and two HTLV-I asymptomatic carriers (right). Serum sampling dates are shown on the X 
axis and antibody titer data (LU) is on the Y-axis.
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Table 2: Sensitivity, specificity, positive and negative predictive values and odds ratio for the anti-Env antibody LIPS test in diagnosing 
HAM/TSP
Comparisons Sensitivity Specificity PPV NPV OR (95% CI)
> 100,000 LU
HAM/TSP vs ATLL & Asymp 81% 72% 75% 79% 11.1 (3.7–33.5)
HAM/TSP vs ATLL 88% 58% 75% 75% 10.5 (2.8–39.4)
HAM/TSP vs Asymp 91% 55% 75% 80% 12.0 (2.8–51.4)
> 200,000 LU
HAM/TSP vs ATLL & Asymp 85% 70% 70% 85% 13.1 (4.1–42.0)
HAM/TSP vs ATLL 90% 56% 70% 83% 11.7 (2.8–47.9)
HAM/TSP vs Asymp 93% 52% 70% 87% 15.2 (3.0–77.9)
Note. PPV, positive predictive value; NPV, negative predictive value; OR, Odds ratio; CI, confidence interval.Retrovirology 2008, 5:96 http://www.retrovirology.com/content/5/1/96
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I virus expression in patients with HAM/TSP reported to
be associated with HTLV-I proviral integration sites that
are not randomly distributed within the human genome
but rather in transcriptionally active regions [31]. It has
been proposed that an individual's steady state rate of
HTLV-I proviral load and the accompanying risk of
inflammatory diseases such as HAM/TSP, are the result of
an equilibrium between HTLV-I replication and the host
immune response [31]. In HAM/TSP, the immune
response is fully engaged so that anti-Env antibody levels
no longer correlate with HTLV-I proviral loads. In asymp-
tomatic carriers, this saturation has not been achieved and
HTLV-I proviral DNA levels highly correlate with antibody
responses.
To date, most studies have found little utility in using anti-
body levels for monitoring disease progression or for sub-
stratifying HTLV-I disease subtypes. Remarkably, in our
study using LIPS, HAM/TSP patients had the highest level
of anti-Env antibodies compared to ATLL or asympto-
matic HTLV-I carriers. Anti-Tax antibodies were only ele-
vated in the HAM/TSP patients compared to the
asymptomatic HTLV-I carriers, but did not markedly differ
with those of the ATLL patients. In contrast, anti-Gag anti-
bodies were relatively similar between the different HTLV-
I-infected patients. While antibody titers and proviral load
have been reported to be higher in HTLV infected patients
from Jamaica compared to Japan [32], simple demo-
graphics can not easily explain the differences in the sub-
groups observed in this study. One implication of these
findings is that anti-Env antibody titers above 100,000 LU
have 75% positive predictive value and 80% negative pre-
dictive value for identifying the HAM/TSP sub-type (odds
ratio, 12.0; 95% CI, 2.8–51.4). High anti-Env antibody tit-
ers were a better marker for HAM/TSP than anti-Tax anti-
bodies, suggesting that the response to Env may have an
important role in the progression to HAM/TSP. Alterna-
tively, surface glycoproteins such as HTLV-I Env may be
more immunogenic than intracellular Tax or Gag pro-
teins. The detection of these high titer anti-Env antibodies
in the HAM/TSP subgroup has not been previously
reported and this is likely due to the fact other immu-
noassay formats such as Western blotting and ELISA
poorly detect conformational epitopes and are not capa-
ble of quantitatively detecting these antibodies. Unlike
published studies [33,34], we did not detect the lack of
antibodies to Tax in ATLL versus asymptomatic carriers.
This discrepancy may be due to the increased sensitivity in
detecting anti-Tax antibodies in the LIPS format.
Previously, molecular mimicry against HTLV-I proteins
was hypothesized to be responsible for HAM/TSP [27,28].
These studies showed that anti-Tax antibodies cross-
reacted with a human protein, HNRNP-A1, associated
with neurons. Based on the success of LIPS in detecting
human autoantibodies associated with neurological dis-
eases [35], the identification of human autoantigens (e.g.
anti-HNRP-A1) associated with HAM/TSP may further
improve the accuracy of this test and thereby potentially
provide a non-invasive method to monitor and predict
disease outcome in HTLV-I-infected patients. It is also
likely that examining HTLV-I antibody and autoantibody
titers in the CSF may provide additional information.
In summary, we have identified a predictive signature for
HAM/TSP that would be economical and easy to imple-
ment in clinical laboratories. Currently we plan on inves-
tigating the contribution of anti-Env and anti-Tax
antibodies in prospective studies of HTLV-I associated dis-
ease. Future studies using LIPS to discover additional
auto-antibodies associated with clinical outcomes of
HTLV-I infection may provide new tools for the predic-
tion, diagnosis and monitoring of these disorders.
Methods
HTLV-infected patients and controls
The sera analyzed were derived from 115 well-character-
ized participants including healthy volunteers, asympto-
matic HTLV-I carriers, ATLL (all subtypes were included
with the majority of samples obtained from patients with
the lymphomatous and acute leukemia subtypes) and
HAM/TSP patients (diagnosed according to WHO guide-
lines) evaluated under Institutional Review Board-
approved protocols of the NCI and NINDS, National
Institutes of Health (Bethesda, MD). The gender, race/eth-
nic group and mean age of sample acquisition are summa-
rized in Table 1. Additional longitudinal samples (n = 76)
were also analyzed blindly from a subset of patients span-
ning a 2 year time period. Sera were kept at -80°C, aliq-
uoted, then stored at 4°C, and measured as anonymous
samples.
Generation of Ruc-antigen fusion constructs
pREN2, a mammalian Renilla luciferase (Ruc) expression
vector, was used to generate all plasmids [36]. HTLV-I
cDNA clones for Gag, Env, reverse transcriptase, p30, p12,
Rex and Tax were amplified by PCR with specific linker-
primer adapters as described [26,36,37]. In each case, con-
structs employed full-length HTLV-I proteins fused to the
carboxy terminus of Ruc. Additional Gag constructs repre-
senting the p24 and p19 processed proteins were also gen-
erated, but were found not to be as diagnostically useful
as the full-length Gag. DNA sequencing was used to con-
firm the integrity of all the plasmid constructs. PCR
primer sequences that were used to generate each con-
struct are available on request.
LIPS analysis
Following transfection of mammalian expression vectors,
crude protein extracts were obtained as described [35]. ForRetrovirology 2008, 5:96 http://www.retrovirology.com/content/5/1/96
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example, the full-length Gag construct yielded extracts
with 1 × 109 light units (LU) of Ruc-Gag protein per 100
mm2 plate of Cos1 cells (sufficient for ~300 serological
tests). The LIPS immunoprecipitation assay was per-
formed in a 96-well plate format at room temperature as
described [37]. First, a "master plate" was constructed by
diluting patient sera 1:10 in assay buffer A (20 mM Tris,
pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100) in
a 96-well polypropylene microtiter plate. For evaluating
antibody titers by LIPS, 40 μl of buffer A, 10 μl of diluted
human sera (1 μl equivalent), and 50 μl of the equivalent
of 1 × 107 light units (LU) of Ruc-antigen Cos1 cell extract,
diluted in buffer A, were added to each well of a polypro-
pylene plate and incubated for 1 hour at room tempera-
ture. Next, 7 μl of a 30% suspension of Ultralink protein
A/G beads (Pierce Biotechnology, Rockford, IL) in PBS
were added to the bottom of each well of a 96-well filter
HTS plate (Millipore, Bedford, MA). To this filter plate,
the 100-μl antigen-antibody reaction mixture was trans-
ferred and incubated for 1 hour at room temperature on a
rotary shaker. The washing steps of the retained protein A/
G beads were performed on a BioMek FX work station
(Beckman Coulter, Fullerton, CA) using an integrated vac-
uum manifold. After the final wash, LU were measured in
a Berthold LB 960 Centro microplate luminometer
(Berthold Technologies, Bad Wilbad, Germany) using
coelenterazine substrate mix (Promega, Madison, WI). All
LU data were obtained from the average of at least two
independent experiments and corrected for background
by subtracting the LU values of beads incubated with Cos1
cell extract, but without sera.
HTLV-I proviral load
Real-time PCR analysis of HTLV-I (Tax) proviral load was
performed as previously described [38]. DNA was
extracted from 1 × 106 cells using Puregene DNA Isolation
Kit (Gentra, Minneapolis, Minnesota, United States), and
100 ng of the sample DNA solution was analyzed by this
system. The HTLV-I proviral DNA load was calculated by
the following formula: copy number of HTLV-I (pX) per
100 cells = (copy number of pX)/(copy number of β-actin/
2) × 100.
Data analysis
The GraphPad Prism software (San Diego, CA) was used
for other statistical analysis, including evaluating test per-
formance by area under the curve (AUC). Results for qual-
itative antibody titers between the controls,
seroindeterminates, asymptomatic HTLV-I carriers, HAM/
TSP and ATLL are reported as the mean ± SD. Mann-Whit-
ney U tests were used for comparison of antibody titers in
different groups. Statistical significance of the regression
analysis was evaluated by Pearson correlation coefficient
and the level of significance was set at P < 0.05. For the cal-
culation of sensitivity and specificity between HTLV-I
infected and uninfected samples, the cut-off limit for each
antigen was derived from the mean value of the 25 control
samples plus 5 standard deviations. The sensitivity, specif-
icity, negative predictive value, positive predictive value
and diagnostic odds ratio were calculated by using 2 × 2
contingency tables and calculated using the GraphPad
software. The multivariate data which included antibody
titers and clinical covariates was also evaluated using the
RapidMiner http://www.rapidminer.com suite of data
mining tools.
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